Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

This phase 1/2 study demonstrated favorable efficacy and low rates of toxicity with low doses of P-BCMA-101 CAR T-cells in patients with RRMM. The favorable safety profile prompted a protocol amendment to allow fully outpatient administration.
This updated analysis of a phase 1, first-in-human study of REGN5458 in heavily pretreated patients with RRMM is consistent with previous findings, showing an acceptable safety profile and deep and durable responses.
The analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) + dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging treatment efficacy that was well tolerated.
Results from a network meta-analysis demonstrated that triple therapy is superior to dual therapy for lenalidomide-refractory patients with multiple myeloma, with the highest efficacy achieved with triple therapy that included a monoclonal antibody.
Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab + Pd reduced the risk for disease progression and death without additional safety signals for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.
Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates.
Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients.
Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%.
The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients.
In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation.
Page 5 of 30
Results 41 - 50 of 292